PCEC awknowledges the newly released draft recommendations from the U.S. Preventative Services Task Force changing prostate-specific antigen (PSA) screening to a level "C" for prostate cancer recognizing that the benefits out weigh the harms for men 55-69 years of age.

Read More

Prostate cancer is a disease that is most successfully treated when it is detected early on.  As the research community explores various methods to detecting the disease, PCEC continues to encourage men to play an active role in their health by looking to those trusted sources of prostate cancer testing – the PSA and DRE.

~Dr. E. David Crawford
Head of the Urologic Oncology Department at the University of Colorado Health Sciences Center
Founder/Chairman of PCEC

Join Our Newsletter